Emotion Regulation as a Moderator of Two Different Treatments for Children With ODD
Launched by UNIVERSITY OF ICELAND · Jan 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different treatments can help children with Oppositional Defiant Disorder (ODD) by focusing on their ability to manage emotions. The researchers want to find out if children do better with a specific type of treatment that matches their emotional challenges. They will divide participants into two groups: one group that has a lot of trouble with emotions and another that has less trouble. Each group will then be randomly assigned to either a parent training program that helps manage behavior or a treatment that teaches problem-solving and emotion regulation skills.
To be eligible for this study, children need to have a diagnosis of Oppositional Defiant Disorder and speak Icelandic with their parent or guardian. The trial is currently recruiting participants aged between 7 and 12 years old. Children who participate can expect to receive one of the two treatments, and their progress will be monitored to see which approach works best for them. It’s important to know that children with an IQ below 70 will not be included in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with Oppositional Defiant Disorder
- • Icelandic speaking (child and parent/guardian)
- Exclusion Criteria:
- • IQ below 70 (full scale score)
About University Of Iceland
The University of Iceland, a leading institution in research and higher education, serves as an innovative sponsor for clinical trials aimed at advancing medical knowledge and improving patient care. With a commitment to rigorous scientific inquiry and ethical standards, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct research across various health disciplines. Collaborating with healthcare professionals and researchers, the University of Iceland fosters an environment that promotes groundbreaking studies, ultimately contributing to the global medical community and enhancing the health outcomes of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reykjavik, , Iceland
Patients applied
Trial Officials
Urdur Njardvik, PhD
Principal Investigator
Department of Psychology, University of Iceland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported